On January 23, 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, reported that Dr. Simon Woodcock, Vice President, Oncology at Redx Pharma, will present at the 2nd Annual Wnt & β-Catenin Pathway Targeted Drug Development Summit (24-26 January, Boston, MA) (Press release, Redx Pharma, JAN 23, 2023, View Source [SID1234626464]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the presentation, which will take place on Thursday 26 January at 10:30 (EST), Dr. Woodcock will discuss the challenges of genetic selection in defined patient populations and how this relates directly to Wnt/β-Catenin Biomarkers in patient selection for clinical studies of targeted therapies, such as Redx’s RXC004.

RXC004 is a clinical stage, highly potent and selective, orally active Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand dependent cancer. It is currently being evaluated in Phase 2 proof-of-concept clinical studies as a monotherapy and in combination with anti-PD-1, Nivolumab, in genetically selected metastatic colorectal cancer (MSS mCRC) (clinicaltrials.gov NCT04907539), as monotherapy in genetically selected pancreatic cancer, and as a monotherapy and in combination with anti-PD-1, Pembrolizumab, in biliary tract cancers (clinicaltrials.gov NCT04907851).

On January 23, 2023 Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to reported the appointment of Matt Cahill MBA JD PhD, as Chief Operating Officer (Press release, Qu Biologics, JAN 23, 2023, View Source;utm_medium=rss&utm_campaign=dr-matt-cahill-appointed-chief-operating-officer-of-qu-biologics [SID1234626463]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am excited to join Qu as the company prepares to initiate multiple phase 2 randomized placebo-controlled studies," said Dr. Cahill. "The Qu platform has the potential to make a profound impact in indications across oncology, inflammation, and infectious disease, and I look forward to supporting the growth of the organization and the expansion of our clinical pipeline."

Prior to joining Qu, Matt was a founding employee of Deep Genomics – a biotechnology company focused on the application of artificial intelligence in drug development. He played a central role in crafting and operationalizing the company’s strategy, helped build the executive team, and led a variety of functions including finance, legal, HR, and business development. During his tenure, the company formed its first Pharma partnerships and raised more than USD$200M through multiple rounds of financing.

Matt received his JD and MBA from the University of Toronto with an emphasis on biotechnology, entrepreneurship, and strategy. He received his PhD from the University of Cambridge, where he studied the genomes of bacteria using novel sequencing technologies.

"The Qu team and I are delighted to welcome Matt as COO at this critical time in Qu’s history, and we look forward to working together," said Dr. Hal Gunn, CEO of Qu Biologics. "His post-graduate degrees in science, law, and business and his past demonstrated success leading biotech finance, business development, and operations make him an excellent match for our needs as we enter the important next phase of our mission to realize the full potential of SSIs."

For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com.

Please subscribe here to receive future news and updates from Qu Biologics.

On January 23, 2023 Philogen reported its attendance at the European Bispecific and Multispecific Antibody congress in Amsterdam (Press release, Philogen, JAN 23, 2023, View Source [SID1234626462]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Roberto De Luca (Head of Antibody Therapeutics at Philochem) is giving a lecture on the 23rd of February 2023 entitled "Engineering Antibody-Cytokine Fusion proteins for Cancer Therapy".
Please follow the link below for more information
View Source

On January 23, 2023 Philogen reported its attendance at the Annual Next-Gen Immuno-Oncology Conference congress in London (Press release, Philogen, JAN 23, 2023, View Source [SID1234626460]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Roberto De Luca (Head of Antibody Therapeutics at Philochem) is giving a lecture on the 9th of March 2023 entitled "Engineering Antibody-Cytokine Fusion proteins for Cancer Therapy".

On January 23, 2023 Lineage Cell Therapeutics its Investors presentation (Presentation, Lineage Cell Therapeutics, JAN 23, 2023, View Source [SID1234626459]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!